Thomas Bärnthaler1, Anna Theiler1, Diana Zabini2, Sandra Trautmann3, Elvira Stacher-Priehse4, Ilse Lanz1, Walter Klepetko5, Katharina Sinn5, Holger Flick6, Stefan Scheidl6, Dominique Thomas3, Horst Olschewski7, Grazyna Kwapiszewska2, Rufina Schuligoi1, Akos Heinemann8. 1. Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria. 2. Division of Physiology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria; Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria. 3. Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University Frankfurt, Frankfurt, Germany. 4. Division of Physiology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria. 5. Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria. 6. Department of Internal Medicine, Division of Pulmonology, Medical University of Graz, Graz, Austria. 7. Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria; Department of Internal Medicine, Division of Pulmonology, Medical University of Graz, Graz, Austria. 8. Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria. Electronic address: akos.heinemann@medunigraz.at.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year mortality and few therapeutic options. Prostaglandin (PG) E2 exhibits antifibrotic properties and is reduced in bronchoalveolar lavage from patients with IPF. 15-Prostaglandin dehydrogenase (15-PGDH) is the key enzyme in PGE2 metabolism under the control of TGF-β and microRNA 218. OBJECTIVE: We sought to investigate the expression of 15-PGDH in IPF and the therapeutic potential of a specific inhibitor of this enzyme in a mouse model and human tissue. METHODS: In vitro studies, including fibrocyte differentiation, regulation of 15-PGDH, RT-PCR, and Western blot, were performed using peripheral blood from healthy donors and patients with IPF and A549 cells. Immunohistochemistry, immunofluorescence, 15-PGDH activity assays, and in situ hybridization as well as ex vivo IPF tissue culture experiments were done using healthy donor and IPF lungs. Therapeutic effects of 15-PGDH inhibition were studied in the bleomycin mouse model of pulmonary fibrosis. RESULTS: We demonstrate that 15-PGDH shows areas of increased expression in patients with IPF. Inhibition of this enzyme increases PGE2 levels and reduces collagen production in IPF precision cut lung slices and in the bleomycin model. Inhibitor-treated mice show amelioration of lung function, decreased alveolar epithelial cell apoptosis, and fibroblast proliferation. Pulmonary fibrocyte accumulation is also decreased by inhibitor treatment in mice, similar to PGE2 that inhibits fibrocyte differentiation from blood of healthy donors and patients with IPF. Finally, microRNA 218-5p, which is downregulated in patients with IPF, suppressed 15-PGDH expression in vivo and in vitro. CONCLUSIONS: These findings highlight the role of 15-PGDH in IPF and suggest 15-PGDH inhibition as a promising therapeutic approach.
BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year mortality and few therapeutic options. Prostaglandin (PG) E2 exhibits antifibrotic properties and is reduced in bronchoalveolar lavage from patients with IPF. 15-Prostaglandin dehydrogenase (15-PGDH) is the key enzyme in PGE2 metabolism under the control of TGF-β and microRNA 218. OBJECTIVE: We sought to investigate the expression of 15-PGDH in IPF and the therapeutic potential of a specific inhibitor of this enzyme in a mouse model and human tissue. METHODS: In vitro studies, including fibrocyte differentiation, regulation of 15-PGDH, RT-PCR, and Western blot, were performed using peripheral blood from healthy donors and patients with IPF and A549 cells. Immunohistochemistry, immunofluorescence, 15-PGDH activity assays, and in situ hybridization as well as ex vivo IPF tissue culture experiments were done using healthy donor and IPF lungs. Therapeutic effects of 15-PGDH inhibition were studied in the bleomycinmouse model of pulmonary fibrosis. RESULTS: We demonstrate that 15-PGDH shows areas of increased expression in patients with IPF. Inhibition of this enzyme increases PGE2 levels and reduces collagen production in IPF precision cut lung slices and in the bleomycin model. Inhibitor-treated mice show amelioration of lung function, decreased alveolar epithelial cell apoptosis, and fibroblast proliferation. Pulmonary fibrocyte accumulation is also decreased by inhibitor treatment in mice, similar to PGE2 that inhibits fibrocyte differentiation from blood of healthy donors and patients with IPF. Finally, microRNA 218-5p, which is downregulated in patients with IPF, suppressed 15-PGDH expression in vivo and in vitro. CONCLUSIONS: These findings highlight the role of 15-PGDH in IPF and suggest 15-PGDH inhibition as a promising therapeutic approach.
Authors: Julianne N P Smith; Matthew D Witkin; Alvin P Jogasuria; Kelsey F Christo; Thomas M Raffay; Sanford D Markowitz; Amar B Desai Journal: Sci Rep Date: 2020-07-15 Impact factor: 4.379
Authors: Amanda Croasdell Lucchini; Naomi N Gachanja; Adriano G Rossi; David A Dorward; Christopher D Lucas Journal: Cells Date: 2021-02-05 Impact factor: 6.600
Authors: Maor Sauler; John E McDonough; Naftali Kaminski; Ivan O Rosas; Taylor S Adams; Neeharika Kothapalli; Thomas Barnthaler; Rhiannon B Werder; Jonas C Schupp; Jessica Nouws; Matthew J Robertson; Cristian Coarfa; Tao Yang; Maurizio Chioccioli; Norihito Omote; Carlos Cosme; Sergio Poli; Ehab A Ayaub; Sarah G Chu; Klaus H Jensen; Jose L Gomez; Clemente J Britto; Micha Sam B Raredon; Laura E Niklason; Andrew A Wilson; Pascal N Timshel Journal: Nat Commun Date: 2022-01-25 Impact factor: 14.919